PhaseV Booth 512 will host a presentation by Hamza Sheikh on accelerating clinical development from synopsis to CSR using a human-guided AI workflow at DPHARM2026 on September 15 at 11:35 a.m. to 11:45 a.m. in Constitution B.
Published
Signal category
Presence & Recognition
Quote
“Accelerating Clinical Development: From Synopsis to CSR with AI”
— PhaseV team
Company
PhaseV
Adaptive. Causal. Intuitive.
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 75 employees
PhaseV is a Boston-based technology company transforming clinical development with an enterprise-ready AI/ML platform that accelerates decisions, de-risks trials, and drives portfolio efficiency. Its Trial Optimizer designs smarter studies, reducing costs by up to 50%, lowering enrollment needs by 40%, shortening timelines by 40%, and boosting probability of success by 30%+. The ClinOps Optimizer enhances site selection by integrating patient-level insights with real-time dashboards to track performance. The Lifecycle Management module combines causal evidence, development complexity, and market value to inform portfolio decisions. Together, these solutions enable sponsors and CROs to optimize every stage of development.